| DB ID | MyCo_5382 |
| Title | Identification of genetic markers of resistance to echinocandins, azoles and 5-fluorocytosine in Candida glabrata by next-generation sequencing: a feasibility study |
| Year | 2017 |
| PMID | 28344162 |
| Fungal Diseases involved | Candida glabrata infection |
| Associated Medical Condition | None |
| Genus | Candida |
| Species | glabrata |
| Organism | Candida glabrata |
| Ethical Statement | None |
| Site of Infection | None |
| Opportunistic invasive | None |
| Sample type | Biopsy |
| Sample source | Extracted genomic DNA |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | FKS1 (S629P) |
| Biomarker Full Name | FKS1 (S629P) |
| Biomarker Type | Diagnostic |
| Biomolecule | Gene |
| Geographical Location | Australia |
| Cohort | Candida glabrata ATCC 90030 and 12 clinical isolates from the culture collection at the Clinical Mycology Reference Laboratory, Westmead Hospital, were retrospectively studied. These include three strain pairs (CMRL-1/CMRL-2, CMRL-3/CMRL-4, CMRL-5/ CMRL-6;) from three patients where antifungal resistance developed during treatment. |
| Cohort No. | 3 |
| Age Group | None |
| P Value | None |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | echinocandin, ≥0.5 mg/L |
| Fold Change | >60-fold |
| Pathway | None |
| Disease Introduction Mechanism | None |
| Technique | Bioinformatics analysis |
| Analysis Method | Next Generation Sequencing Approach |
| ELISA kits | None |
| Assay Data | None |
| Validation Techniques used | Next Generation Sequencing Approach |
| Up Regulation Down Regulation | Positive |
| Sequence Data | None |
| External Link | None |
